[Bio Feature Article] Exosome-Based Biotech Firm A-Bio Materials Sets Sights on Global Expansion with Strategic Investment from Shinsegae International

A-Bio Materials, a Seoul-based developer of exosome-derived biomaterials, has closed a Series C financing with strategic participation from Shinsegae International and the Shinsegae Group’s venture arm, SIGNITE, the company announced.

The investment is earmarked to accelerate the company’s move into higher-margin medical devices and to underpin a planned public listing on Korea’s KOSDAQ market.

Founded in 2020, A-Bio Materials designs and manufactures exosome and PDRN (polydeoxyribonucleotide) ingredients derived from a range of biological sources, including human cells, plants and microbes.